nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-A3A2ABED·Framework v5.9·Pipeline v0.4·Evaluated 25 Sept 2026·OECD: 3.1 Basic medicine·Subfield: Genetics·Basis: Full text·Type: Randomized controlled trial

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study

Timothy J Craig et al.Timothy J Craig, Donald S Levy, Avner Reshef et al.·2024·The Lancet Haematology·10.1016/s2352-3026(24)00081-4 ↗

Primary claim

Once-monthly garadacimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL.

Supported · large sustained observed reductions, but uncontrolled open-label follow-up limits causal efficacy and HRQoL inference
In brief

Long-term garadacimab follow-up adds clinically useful durability and tolerability evidence, but the uncontrolled open-label extension limits causal efficacy and HRQoL conclusions.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract not available — view at DOI ↗

Key Claims

Primary finding · Supported

Once-monthly garadacimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

large sustained observed reductions, but uncontrolled open-label follow-up limits causal efficacy and HRQoL inference

Summary, Interpretation, p e436
Quote verified
Secondary · Supported

Median reduction in monthly attack rate versus run-in was 100% (IQR 98–100) with garadacimab 200 mg.

directly reported descriptive result, though the before–after extension design limits causal interpretation

Summary, Findings, p e436; Results, p e442
Quote verified
Secondary · Supported

HRQoL improvements observed during TP1 with garadacimab were sustained throughout TP2.

longitudinal AE-QoL and WPAI patterns support persistence, but open-label patient reporting permits expectation effects

Summary, Findings, p e436; Figure 3
Quote verified
Secondary · Supported

TP2 safety signals were consistent with TP1.

systematic adverse-event reporting supports consistency, while the small cohort cannot characterise uncommon harms

Summary, Findings, p e436; Table 2
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Long-duration evidence for monthly prophylaxis

TP2 provides attack-rate, quality-of-life, and tolerability observations over extended exposure, with treatment lasting as long as 129 weeks across the full study.

↳ Research in context, p e437; Results, p e442

#methodological rigour

Transparent handling of dose transitions

The protocol-mandated reduction from 600 mg to 200 mg and the resulting overlapping dose-group assignments are explained in the Methods, trial profile, and table and figure notes.

↳ Methods, pp e439–41; Figure 1; Table 1

#methodological rigour

Systematic long-term harms reporting

Adverse events were coded, graded, exposure-adjusted, and reported alongside prespecified events of special interest, with independent safety-board oversight.

↳ Methods, pp e439–41; Table 2

Limitations

#methodological rigour

No concurrent control during long-term follow-up

TP2 used an open-label, uncontrolled design with descriptive analysis only, so sustained attack-rate and HRQoL observations cannot independently establish long-term causal efficacy.

↳ Methods, pp e438–40; Discussion, p e445

#methodological rigour

Subjective outcomes remain expectation-sensitive

AE-QoL, WPAI, SGART, and IGART were collected while participants and investigators knew active treatment was being received, without a reported mitigation strategy.

↳ Outcomes, pp e439–40; Discussion, p e445

#application pathway

Small and demographically narrow cohort

The extension included 38 adults, 87% of whom were White, limiting transferability and the ability to characterise uncommon harms.

↳ Table 1, p e441; Discussion, p e445

Does this match your read? Add your assessment ↓

Nabu Commentary

The paper makes a useful incremental contribution by extending garadacimab observations beyond the previously reported controlled treatment period and phase 3 trial. Its strongest execution features are transparent dose-transition accounting, low attrition, prespecified safety surveillance, and exposure-adjusted adverse-event reporting. The principal methodological constraint is TP2's uncontrolled open-label design, particularly for AE-QoL, SGART, IGART, and WPAI outcomes. The score also reflects that the limitations paragraph names this design issue but the abstract and conclusion retain stronger efficacy language than TP2 alone can support.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.5±0.1

Contribution
3.6

The study adds up to 129 weeks of efficacy, HRQoL, and safety observations for a novel factor XIIa-targeting prophylactic therapy. This is a clinically relevant but incremental extension of previously published phase 2 and phase 3 efficacy evidence.

Research in context, pp e437–38; Results, pp e442–45

the results of this study provide the first long-term safety and efficacy data for this molecule

Methodological Rigour
3.4

The study transparently reports randomisation, dose transitions, analysis populations, low attrition, and systematic adverse-event ascertainment. TP2 remains open-label and uncontrolled, exposing AE-QoL, SGART, IGART, and WPAI results to expectation effects.

Methods, pp e438–41; Figure 1; Table 2

Descriptive statistics with no hypothesis testing were performed for TP2.

Reporting
3.7

The paper clearly separates the controlled TP1 period from the descriptive TP2 extension and explains the protocol amendment and overlapping dose groups. The abstract nevertheless uses affirmative long-term efficacy and HRQoL language without carrying the design qualification directly into the interpretation.

Summary, p e436; Methods, pp e438–41

was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL

Positioning
3.3

The paper situates the findings among guidelines, existing prophylactic therapies, prior phase 2 evidence, and VANGUARD. It names the small sample, limited racial representation, open-label design, and overlapping groups, but does not fully trace the open-label limitation into the certainty of its conclusions.

Research in context, p e437; Discussion, p e445

Further limitations are the open-label nature of TP2

Lower confidence on Reporting, Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Internal CoherenceClean

Participant flow, overlapping dose-group denominators, protocol-mandated down-titration, and adverse-event totals are internally consistent and transparently explained. No statistical impossibility or material methods–results mismatch was identified.

Research ConductNoted

Ethics approval, consent, prospective registration, conflicts, and sponsor roles are disclosed. The sponsor's direct participation in study design, data collection, analysis, interpretation, manuscript review, and funded medical writing is a disclosed structural consideration.

Flags: 4 declared / 5 total

Reference IntegrityClean

25 of 25 checkable references verified

25 references in manuscript

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesCatch-all cause
CitationsFWCI 5.3
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The long-term claim rests on a small open-label extension of 38 patients without a control group, while the independent phase 3 trial only corroborated six months of treatment.

From the paper
“These results support the use of garadacimab at a dose of 200 mg once monthly as a potential prophylactic therapy for patients with hereditary angioedema.”

The paper names patients and physicians as those who would use garadacimab 200 mg once monthly as long-term prophylactic therapy for hereditary angioedema.

Pathway

Physicians treating hereditary angioedema would prescribe once-monthly self-administered garadacimab 200 mg as long-term prophylaxis, pending regulatory approval and confirmatory phase 3 extension data.

Barrier

The long-term evidence comes from a small, open-label, single-arm extension without placebo comparison, so regulatory approval and the ongoing phase 3 open-label extension are still needed.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →